Recent research has implicated the gut microbiota in the development of lymphoma. Dysbiosis of the gut microbial community can disrupt the production of gut microbial metabolites, thereby impacting host physiology and potentially contributing to lymphoma. Dysbiosis-driven release of gut microbial metabolites such as lipopolysaccharides can promote chronic inflammation, potentially elevating the risk of lymphoma. In contrast, gut microbial metabolites, such as short-chain fatty acids, have shown promise in preclinical studies by promoting regulatory T-cell function, suppressing inflammation, and potentially preventing lymphoma. Another metabolite, urolithin A, exhibited immunomodulatory and antiproliferative properties against lymphoma cell lines in vitro. While research on the role of gut microbial metabolites in lymphoma is limited, this article emphasizes the need to comprehend their significance, including therapeutic applications, molecular mechanisms of action, and interactions with standard chemotherapies. The article also suggests promising directions for future research in this emerging field of connection between lymphoma and gut microbiome.
近期研究表明，肠道微生物群与淋巴瘤的发生发展存在关联。肠道菌群失调可干扰肠道微生物代谢产物的生成，进而影响宿主生理状态，并可能促进淋巴瘤发生。菌群失调导致的脂多糖等微生物代谢产物释放可能诱发慢性炎症，从而增加淋巴瘤患病风险。与之相反，短链脂肪酸等肠道微生物代谢产物在临床前研究中展现出潜在价值，可通过增强调节性T细胞功能、抑制炎症反应来预防淋巴瘤发生。另一代谢产物尿石素A在体外实验中显示出对淋巴瘤细胞系的免疫调节及抗增殖特性。尽管目前关于肠道微生物代谢产物在淋巴瘤中作用的研究尚不充分，本文强调需要深入理解其重要意义，包括治疗应用潜力、分子作用机制以及与标准化疗方案的协同效应。文章同时展望了这一新兴领域——淋巴瘤与肠道微生物组关联研究的未来发展方向。
肿瘤(癌症)患者之家